RecruitingNCT05953558

French Cohort Evaluating the effectiveneSs of Atrioventricular Synchrony by the micRa AV

Cohorte Française Des Patients Implantés de Micra AV


Sponsor

Paris Sudden Death Expertise Center

Enrollment

1,000 participants

Start Date

May 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Transvenous cardiac pacemakers have pitfalls due to lead- and device pocket-related complications. Leadless pacemakers were developed and introduced into clinical practice to overcome the weaknesses of traditional transvenous pacemakers. The absence of atrial pacing has restricted their uses mainly for cases of paroxysmal atrioventricular block (AVB) or AVB with atrial fibrillation. The Micra AV contains an embedded accelerometer that senses the atrial contraction waveform, allowing the ventricle to be paced once the atrial contraction is complete. This atrioventricular synchronization is intended to extend the use of the device to cases of permanent complete AVB with normal sinus function. Two randomized clinicals trials have been proven it's efficacy. However, with AV-CESAR cohort, we aim to evaluate the real word effectiveness of Micra AV, in the first 1000 patients implanted by the device in France.


Eligibility

Min Age: 18 YearsMax Age: 110 Years

Inclusion Criteria1

  • All patients who underwent Micra AV implantation

Exclusion Criteria1

  • Refusal of consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPatients implanted with Micra AV

The first 1000 patients implanted by the device in France


Locations(1)

Paris Cardiovascular Research Centre (AV-CESAR Investigators)

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05953558